The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study-Reference-Cited by-同舟云学术

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study

Published:2008-06 Issue:6 Volume:38 Page:557-564
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Iwasaki Shinji,Ohira Hiromasa,Nishiguchi Shuhei,Zeniya Mikio,Kaneko Shuichi,Onji Morikazu,Ishibashi Hiromi,Sakaida Isao,Kuriyama Shigeki,Ichida Takafumi,Onishi Saburo,Toda Gotaro,

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1872-034X.2007.00305.x/fullpdf

Reference22 articles.

1. A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis

2. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

3. Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients

4. Long-Term Effects of Mid-Dose Ursodeoxycholic Acid in Primary Biliary Cirrhosis: A Meta-analysis of Randomized Controlled Trials

5. Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PPAR agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;2024-05-14

2. Treatment of Primary Biliary Cholangitis including Transplantation;Clinics in Liver Disease;2024-02

3. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis;Systematic Reviews;2024-01-29

4. The treatment of primary biliary cholangitis: from shadow to light;Therapeutic Advances in Gastroenterology;2024-01

5. Efficacy and Safety of PPAR Agonist in Fibrosing Cholangiopathies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;2024